Drug intelligence / Profile preview

rosuvastatin + ezetimibe

Development stage: Phase 4
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-220 is an Addpharma fixed-dose oral lipid-lowering combination of rosuvastatin 2.5 mg and ezetimibe 10 mg being developed for hyperlipidemia. Rosuvastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, reducing hepatic cholesterol synthesis, while ezetimibe inhibits Niemann-Pick C1-like 1-mediated intestinal cholesterol absorption. A completed randomized Phase 1 pharmacokinetic study compared the fixed-dose combination with coadministration of its individual components in healthy volunteers. (tcpharm.org)

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)ATP4B (Potassium-transporting ATPase subunit beta)DDAH (Dimethylarginine dimethylaminohydrolase 1)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on rosuvastatin + ezetimibe.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rosuvastatin + ezetimibe.